Form 4: Olema Director Cyrus Harmon Sells 25,000 Shares

Olema Pharmaceuticals Director Cyrus Harmon reported multiple sales of common stock totaling 25,000 shares in mid-September 2025, executed under a Rule 10b5-1 plan.

Summary

• Cyrus Harmon, a Director of Olema Pharmaceuticals, Inc. (OLMA), reported the sale of 25,000 shares of common stock.
• The transactions occurred on September 16, 2025, and September 18, 2025.
• Sales included 10,000 shares directly owned at a weighted average price of $8.04, and another 10,000 shares directly owned at a weighted average price of $8.33.
• Additionally, 1,914 shares indirectly owned were sold at a weighted average price of $8.08, and 3,086 shares indirectly owned were sold at a weighted average price of $8.32.
• The indirect shares are held by Harmon Family Investors LLC, where Mr. Harmon serves as manager.
• Following these transactions, Cyrus Harmon beneficially owns 744,140 shares directly and 117,028 shares indirectly.
• All reported transactions were made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.

Sentiment

Score: 5

Explanation: The sales by Director Cyrus Harmon were conducted under a pre-arranged Rule 10b5-1 trading plan, which typically indicates a scheduled diversification or liquidity event rather than a reaction to new material non-public information. While insider selling can sometimes be viewed negatively, the 10b5-1 plan mitigates concerns about immediate negative sentiment, leading to a neutral score.

Positives

• The transactions were executed pursuant to a Rule 10b5-1(c) plan, indicating pre-scheduled sales rather than a reaction to new, potentially negative, company information, which enhances transparency.

Negatives

• A director reducing their stake, even if pre-planned, can be interpreted by some investors as a signal of reduced confidence or a desire to diversify away from the company.

Risks

• Insider selling, even under a 10b5-1 plan, can sometimes lead to negative market sentiment or speculation regarding the company's future prospects.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This insider transaction report is specific to Olema Pharmaceuticals and Director Cyrus Harmon and does not provide broader industry context or trends.

Related Party Transactions

• Shares indirectly owned by Cyrus Harmon are held through Harmon Family Investors LLC, where the Reporting Person serves as manager.

Stakeholder Impact

• Shareholders might perceive the director's sales as a negative signal, potentially leading to short-term price volatility, despite the 10b5-1 plan.

Key Dates

Recommendation

The director's sales were executed under a Rule 10b5-1 plan, suggesting these are pre-scheduled transactions for personal financial planning rather than a signal of deteriorating company fundamentals. Investors should not interpret these sales as a direct negative indicator for Olema Pharmaceuticals, but rather as a routine insider diversification event. The underlying investment thesis for OLMA remains unchanged by this filing.

Keywords

Olema Pharmaceuticals, OLMA, Cyrus Harmon, Director, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Common Stock